Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer: a Prospective，Multicentre, Single-arm Study

NCT06613165 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06613165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06613165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer: a Prospective，Multicentre, Single-arm Study
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2025
Completion date
September 20, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dmmr colorectal cancer, immune-related adverse event, neoadjuvant therapy